HC Wainwright Issues Optimistic Forecast for CLDX Earnings

Key Points

• HC Wainwright raised its Q3 2026 EPS estimate for Celldex Therapeutics to a loss of $1.05 per share from $1.12, while maintaining a Buy rating and $42 price target.
• Celldex reported a Q2 loss of $0.94 per share, beating the $1.06 consensus estimate by $0.12, though quarterly revenue of $0.02 million fell short of the $0.73 million forecast.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and $55.46 price target; shares recently traded near $42.97, close to their 12-month high of $43.21.

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Equities researchers at HC Wainwright upped their Q3 2026 EPS estimates for shares of Celldex Therapeutics in a research note issued on Friday, August 7th. HC Wainwright analyst J. Pantginis now forecasts that the biopharmaceutical company will post earnings of ($1.05) per share for the quarter, up from their previous forecast of ($1.12). HC Wainwright has a "Buy" rating and a $42.00 price objective on the stock. The consensus estimate for Celldex Therapeutics' current full-year earnings is ($4.36) per share. HC Wainwright also issued estimates for Celldex Therapeutics' Q4 2026 earnings at ($1.08) EPS, FY2026 earnings at ($4.23) EPS and FY2027 earnings at ($4.49) EPS.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter, beating analysts' consensus estimates of ($1.06) by $0.12. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.73 million.

A number of other research firms have also recently weighed in on CLDX. UBS Group raised their price target on Celldex Therapeutics from $38.00 to $45.00 and gave the company a "buy" rating in a research note on Wednesday, June 10th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Celldex Therapeutics in a report on Friday, July 17th. Morgan Stanley boosted their target price on Celldex Therapeutics from $40.00 to $46.00 and gave the stock an "overweight" rating in a research note on Friday. Wells Fargo & Company upped their price target on Celldex Therapeutics from $48.00 to $72.00 and gave the company an "overweight" rating in a report on Wednesday, July 29th. Finally, Wall Street Zen upgraded shares of Celldex Therapeutics from a "strong sell" rating to a "sell" rating in a research note on Sunday, July 12th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Celldex Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $55.46.

Celldex Therapeutics Trading Up 3.0%

Shares of CLDX stock opened at $42.97 on Tuesday. The company has a market cap of $3.37 billion, a P/E ratio of -9.88 and a beta of 0.87. The firm has a fifty day moving average price of $35.45 and a 200 day moving average price of $31.70. Celldex Therapeutics has a 12 month low of $19.72 and a 12 month high of $43.21.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CLDX. Russell Investments Group Ltd. lifted its stake in Celldex Therapeutics by 27.6% in the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company's stock valued at $47,000 after buying an additional 501 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Celldex Therapeutics by 1.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company's stock worth $798,000 after acquiring an additional 680 shares during the last quarter. ProShare Advisors LLC increased its holdings in shares of Celldex Therapeutics by 6.9% in the 4th quarter. ProShare Advisors LLC now owns 11,973 shares of the biopharmaceutical company's stock valued at $325,000 after acquiring an additional 773 shares during the period. Handelsbanken Fonder AB increased its holdings in shares of Celldex Therapeutics by 5.0% in the 2nd quarter. Handelsbanken Fonder AB now owns 27,200 shares of the biopharmaceutical company's stock valued at $1,012,000 after acquiring an additional 1,300 shares during the period. Finally, Panagora Asset Management Inc. raised its position in Celldex Therapeutics by 7.5% in the 4th quarter. Panagora Asset Management Inc. now owns 21,856 shares of the biopharmaceutical company's stock valued at $594,000 after purchasing an additional 1,522 shares during the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company's research platforms leverage novel antibody and vaccine technologies designed to engage the patient's immune system, with a particular emphasis on oncology and neurologic indications. Celldex's pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex's lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source